CN115734787A - 治疗与阿尔茨海默氏病相关的激越的方法 - Google Patents

治疗与阿尔茨海默氏病相关的激越的方法 Download PDF

Info

Publication number
CN115734787A
CN115734787A CN202180045685.XA CN202180045685A CN115734787A CN 115734787 A CN115734787 A CN 115734787A CN 202180045685 A CN202180045685 A CN 202180045685A CN 115734787 A CN115734787 A CN 115734787A
Authority
CN
China
Prior art keywords
patient
cmai
score
administering
administering step
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180045685.XA
Other languages
English (en)
Chinese (zh)
Inventor
桑贾伊·杜贝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avanir Pharmaceuticals Inc
Original Assignee
Avanir Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals Inc filed Critical Avanir Pharmaceuticals Inc
Publication of CN115734787A publication Critical patent/CN115734787A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180045685.XA 2020-04-27 2021-04-26 治疗与阿尔茨海默氏病相关的激越的方法 Pending CN115734787A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063016270P 2020-04-27 2020-04-27
US63/016,270 2020-04-27
PCT/US2021/029246 WO2021222145A1 (en) 2020-04-27 2021-04-26 Methomethods of treating agitation associated with alzheimer's disease

Publications (1)

Publication Number Publication Date
CN115734787A true CN115734787A (zh) 2023-03-03

Family

ID=75914613

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180045685.XA Pending CN115734787A (zh) 2020-04-27 2021-04-26 治疗与阿尔茨海默氏病相关的激越的方法

Country Status (13)

Country Link
US (1) US20230270738A1 (enExample)
EP (1) EP4142729A1 (enExample)
JP (1) JP2023523373A (enExample)
KR (1) KR20230016636A (enExample)
CN (1) CN115734787A (enExample)
AU (1) AU2021263354A1 (enExample)
BR (1) BR112022021535A2 (enExample)
CA (1) CA3176234A1 (enExample)
IL (1) IL296977A (enExample)
MX (1) MX2022013427A (enExample)
PH (1) PH12022552764A1 (enExample)
TW (1) TW202203922A (enExample)
WO (1) WO2021222145A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115322150A (zh) * 2021-05-11 2022-11-11 深圳信立泰药业股份有限公司 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2792662T3 (da) 2007-05-01 2016-07-25 Concert Pharmaceuticals Inc Morphinanforbindelser
KR20240110812A (ko) * 2021-10-27 2024-07-16 아바니르 파마슈티컬스, 인코포레이티드 알츠하이머병과 관련된 불안을 치료하는 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110664801A (zh) * 2014-09-14 2020-01-10 阿瓦尼尔制药股份有限公司 用于治疗痴呆中的激越行为的包含右美沙芬化合物和奎尼丁的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
US20160143901A1 (en) * 2006-02-03 2016-05-26 Avanir Pharmaceuticals, Inc. Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementia
MX370608B (es) 2007-05-01 2019-12-18 Concert Pharmaceuticals Inc Compuestos de morfinano.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110664801A (zh) * 2014-09-14 2020-01-10 阿瓦尼尔制药股份有限公司 用于治疗痴呆中的激越行为的包含右美沙芬化合物和奎尼丁的药物组合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115322150A (zh) * 2021-05-11 2022-11-11 深圳信立泰药业股份有限公司 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途
CN115322150B (zh) * 2021-05-11 2024-05-28 深圳信立泰药业股份有限公司 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途

Also Published As

Publication number Publication date
EP4142729A1 (en) 2023-03-08
IL296977A (en) 2022-12-01
WO2021222145A1 (en) 2021-11-04
BR112022021535A2 (pt) 2023-01-24
US20230270738A1 (en) 2023-08-31
KR20230016636A (ko) 2023-02-02
TW202203922A (zh) 2022-02-01
WO2021222145A8 (en) 2021-12-30
PH12022552764A1 (en) 2024-03-25
MX2022013427A (es) 2023-01-19
AU2021263354A1 (en) 2022-10-27
JP2023523373A (ja) 2023-06-02
CA3176234A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
Bhana et al. Olanzapine: an updated review of its use in the management of schizophrenia
KR102316933B1 (ko) 헌팅턴병 치료를 위한 프리도피딘의 용도
CN112057441A (zh) 创伤后应激障碍的治疗方法
JP2026050474A (ja) Ｎｍｄａ拮抗薬の副作用の低減
Streim et al. Drug treatment of depression in frail elderly nursing home residents
US20230270738A1 (en) Methods of treating agitation associated with alzheimer's disease
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
AU2018383098A1 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
JP2022526101A (ja) 重水素化デキストロメトルファン及びキニジンを使用して統合失調症の陰性症状を治療する方法
US20070185080A1 (en) Pharmaceutical Compositions
US20230131493A1 (en) Methods of treating agitation associated with alzheimer's disease
TW202310825A (zh) 減少ｎｍｄａ受體拮抗劑之副作用
EP2694065B1 (en) Composition for treating hypoactive sexual desire disorder
Haghparast et al. Sedatives and hypnotics
US20240408086A1 (en) Use of luvadaxistat for the treatment of cognitive impairment
HK40089955A (en) Methods of treating agitation associated with alzheimer's disease
CN118510513A (zh) 治疗与阿尔茨海默氏病相关的激越的方法
Narang et al. Pharmacotherapy for Insomnia
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
WO2011051423A1 (en) Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy
Hydrochloride et al. Submission Control No: 200951
PRESCRIBED Change for
Tablets et al. PrACT BUPROPION XL
Spectr w ww. cnsspectrums. com https://doi. org/10.1017/S1092852900028388 Published online by Cambridge University Press
Tablets FULL PRESCRIBING INFORMATION: CONTENTS* SUICIDALITY AND ANTIDEPRESSANT DRUGS 1 INDICATIONS AND USAGE

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40089955

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230303